个人简介：纪泛扑，男，41岁，医学博士，副教授，副主任医师，硕士生导师，美国斯坦福大学访问学者，AASLD会员，第十三届陕西省青年科技奖获得者，西安交通大学医学部国家级后备人才。现任西安交通大学第二附属医院学科建设办公室主任；陕西省感染性疾病临床医学研究中心副主任。World Journal of Hepatology杂志编委，《中华实验与临床感染病杂志》编委，《中国肝脏病杂志》青年编委，Clinical Gastroenterology and Hepatology、Alimentary Pharmacology and Therapeutics、Liver International、Journal of Viral Hepatitis、European Journal of Gastroenterology & Hepatology、BMC Infectious Diseases、Drug Design, Development and Therapy、Viral Immunology、Journal of Medical Virology、OncoTargets and Therapy、World Journal of Gastroenterology、International Journal of Immunopathology and Pharmacology、《临床肝胆病杂志》等杂志审稿人。2018年在华盛顿DDW口头报告1次，2020、2019、2018、2016在APASL口头报告5次。
工作履历：
2016/01-至今，西安交通大学第二附属医院感染科，副主任医师
2009/12-2015/12，西安交通大学第二附属医院感染科，主治医师
2006/07-2009/11，西安交通大学第二附属医院感染科，住院医师
教学履历
担任5年制/5+3/8年制大课教学，2016年获批硕士导师资格，目前已协助培养博士生5名、独立指导硕士生4名（已毕业1名），指导6名本科生参与临床科研项目并在SCI收录期刊参与发表论文3篇。
学会任职
陕西省性学会青年专家委员会副主任委员，陕西省传染病与寄生虫病学会青年委员，陕西省肝病学会自免肝学组委员，西安市感染症学会常务委员，西安市肝病学会委员。
获得荣誉和主要科研成果奖励
2020.10陕西省科协第十三届陕西省青年科技奖
2020.09中华医学会第十六次全国感染病年会优秀论文二等奖
2020.04临床肝胆病杂志2017-2019年优秀审稿专家
2019.08西安交通大学国家级人才后备人选菁英计划
2018.07中华医学会第十五次全国感染病年会优秀论文二等奖
2016.06陕西省卫健委陕西省城乡医院对口支援工作先进个人
2016.09西安交通大学临床医疗技术一等奖（主持）
2015.03陕西省科技厅陕西省科技进步奖一等奖（参与）
承担主要科研课题
1.项目名称：新型冠状病毒肺炎重症化预测指标及间充质干细胞干预治疗新策略与机制探讨
项目编号：No.xzy032020040
经费来源：中央高校基本科研业务费新冠病毒应急科研项目，30万
起止年月：2020/02-2021/01
2.项目名称：西安交通大学医学部国家级后备人才（菁英计划）
项目编号：No.XJTURC201905
经费来源：西安交通大学医学部，50万
起止年月：2019.7-2022.06
3.项目名称：妊娠合并HTNV感染对孕妇和胎儿预后的影响
项目编号：No.xzy012019107
经费来源：中央高校基本科研业务费，12万
起止年月：2019.1-2021.12
4.项目名称：Real-world Evidence from the Asia Liver Consortium for HCV
项目编号：733559
经费来源：Stanford University and Gilead Sciences, Inc，1.75万美元
起止年月：2018.8.1-2020.7.31
5.项目名称：丙型肝炎肝硬化脾亢脾抑制T细胞功能诱导机体免疫耐受
项目编号：2017JM8092
经费来源：陕西省自然科学基金（面上项目），3万
起止年月：2017.1-2018.12
6.项目名称：脾切除改善丙型肝炎失代偿期肝硬化抗病毒应答的免疫机制研究
项目编号：81300322
经费来源：国家自然科学基金青年项目，23万
起止年月：2014.1-2016.12
近3年发表主要学术论文(#共同第一作者，*通讯作者)
1.Fanpu Ji,Jie Li, Li Liu, Jing Liang, Xiaozhong Wang, Junping Liu, Dachuan Cai, Rui Huang, Jiajie Zhang, Qi Wang, Yuemin Nan, Junyi Li, Qing Ye, Mingyuan Zhang, Qiang Xu, Feng Guo, Changqing Zhao, Lingdi Liu, Caini He, Yu Li, Wenjun Wang, Leslie Y. Kam, Sally Tran, Mayumi Maeda, Akiko Mizuta, Zongfang Li, Shuangsuo Dang, Wanhua Ren, Qiang Zhu, Ramsey Cheung, Junqi Niu, Wen Xie, Hongying Pan, Hong Ren, Chao Wu, Jia Shang, Fengmei Wang, Mindie H. Nguyen*. High HCV cure rates with approved interferon‐free direct acting antivirals among diverse Mainland Chinese patients including genotypes 3a and 3b.J Gastroenterol Hepatol,2020, 22 July.https://doi.org/10.1111/jgh.15192.(IF 3.437)
2.Jin Yan#,Fanpu Ji#,Siqi Yan#, Weiming You, Fang Ma, Fanni Li, Yinong Huang, Wenjia Liu*, Wangxiao He*. A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics.Theranostics,2020;10(19):8513-8527.(IF 8.579)
3.Zu J*,Li ML, Li ZF, Shen MW, Xiao YN,Ji FP*.Transmission patterns of COVID-19 in the mainland of China and the efficacy of different control strategies: a data- and model-driven study.Infect Dis Poverty.2020;9(1):83.(IF 3.067)
4.Zeng QL*#, Li GM#,Ji FP#,Ma SH#, Zhang GF#, Xu JH#, Lin WB#, Xu GH#, Zhang GQ, Li GT, Cui GL, Liu N, Zeng FJ, Ai ZG, Xu GF, Liu N, Liang J, Zhang MM, Li C, Zhang ZH, Wang ZS, Li Z, Yu ZJ*. Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.Transbound Emerg Dis.2020 Jun 12:10.1111/tbed.13674.(IF 4.118)
5.Ji FP,Li LY, Li ZF, Jin Y*, Liu WJ*. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019.Stem Cells Transl Med.2020; 9(7):813-814.(IF 6.429)
6.Liu Yuanyuan, Li Yongqin, Wang Qiaoxia, Fu Jianjun,Ji Fanpu*.Sporadic human cutaneous anthrax outbreak in Shaanxi Province, China: report of two cases from 2018.Braz J Infect Dis.2020;24(1):81-84.(IF 1.971)
7.Ji Fanpu,#Yeo Yee Hui,#Wei Mike Tzuhen, Ogawa Eiichi, Enomoto Masaru, Lee Dong Hyun, Iio Etsuko, Lubel John, Wang Wenjun, Wei Bin, Ide Tatsuya, Preda Carmen Monica, Conti Fabio, Minami Tatsuya, Bielen Rob, Sezaki Hitomi, Barone Michele, Kolly Philippe, Chu Po-sung, Virlogeux Victor, Eurich Dennis, Henry Linda, Bass Michelle B, Kanai Takanori, Dang Shuangsuo, Li Zongfang, Dufour Jean-François, Zoulim Fabien, Andreone Pietro, Cheung Ramsey, Tanaka Yasuhito, Furusyo Norihiro, Toyoda Hidenori, Tamori Akihiro, Nguyen Mindie*. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.J Hepatol.2019;71(3):473-485.(IF:20.582).
8.Ji Fanpu, Yeo Yee Hui, He Caini, Li Jie, Gao Xuesong, Li Zongfang, Henry Linda, Nguyen Mindie. Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.J Hepatol.2019;70(1):209-211.(IF: 20.582).
9.Huang Na,#Ji Fanpu,#Zhang Shu, Li Zhenzhen, Li Jun, Zhou Rui, Zhang Shaoying, Wei Wei, Li Liang, Chen Haiyuan, Li Baohua, Kong Guangyao, Yang Jun, Li Zongfang. Spleen-Associated Effects on Immunity in Hepatitis B Virus-Related Cirrhosis with Portal Hypertension.J Interferon Cytokine Res.2019;39(2):95-105.(IF:2.032)
10.Ji Fanpu,#Wei Bin,#Yeo Yee Hui, Ogawa Eiichi, Zou Biyao, Stave Christopher D, Li Zongfang, DangShuangsuo, Furusyo Norihiro, Cheung Ramsey C, Nguyen Mindie H.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Aliment Pharmacol Ther.2018;47(5):550-562. (IF 7.731)
11.Ji Fanpu,Yeo Yee Hui, Wei Mike Tzuhen, Wei Bin, Dang Shuangsuo, Li Zongfang, Nguyen Mindie H. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?Hepatology.2018; 67(3):1180-1182. (IF 14.971)
12.Wei Bin,#Ji Fanpu,#Yeo Yee Hui, Ogawa Eiichi, Zou Biyao, Stave Christopher D, Dang Shuangsuo, Li Zongfang, Furusyo Norihiro, Cheung Ramsey, Nguyen Mindie. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis.BMJ Open Gastroenterol.2018; 5(1):e000207.
13.Huang Na,#Ji Fanpu,#Zhang Shu, Pu Yansong, Jiang An, Zhou Rui, Ji Yuanyuan, Wei Wei, Yang Jun, Li Zongfang. Effect of splenectomy on serum cytokine profiles in hepatitis B virus-related cirrhosis patients with portal hypertension.Viral Immunol.2018;31(5):371-378.(IF 1.417)
14.Ji Fanpu,Zhao Wenxuan, Liu Hailing, Zheng Hongbo, Wang Shengbang, He Caini, Wang Wenjun, Zhang Ruijuan, Bai Dan, Tian Changyin, Zhao Wenxue, Deng Hong. Hemorrhagic fever with renal syndrome caused by Hantaan virus infection in four pregnant Chinese women.J Med Virol.2017;89(10):1865-1870.(IF:1.988)
15.Ji Fanpu,Zhou Rui, Wang Wenjun, Bai Dan, He Caini, Cai Zhifang, Shen Yuan, Wang Shengbang, Deng Hong, Li Zongfang. High post-treatment α-fetoprotein levels and aspartate aminotransferase-to-platelet ratio index predict hepatocellular carcinoma in hepatitis C virus decompensated cirrhotic patients with sustained virological response after antiviral therapy.J Interferon Cytokine Res.2017; 37(8): 362-368.(IF:2.419)
16.Ji Fanpu,Wang Wenjun, Dang Shuangsuo, Wang Shengbang, Li Burong, Bai Dan, Zhao Wenxue, Deng Hong, Tian Changyin, Li Zongfang. Outcomes after sofosbuvir containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real world study.Infect Agent Cancer.2017;12:48.(IF:2.123)
17.高旭，纪泛扑*.直接抗病毒药物时代丙型肝炎相关肝细胞癌的诊治对策.中华肝脏病杂志，2020,28(10):827-830.
18.赵蕴玉，贺彩妮，高培根，刘莹，姚雷清，高蓉，刘佳姝，魏伏，李慎，朱龙飞，李政霄，纪泛扑*.直接抗病毒药治疗丙型肝炎相关性皮肤损害：回顾性病例系列研究.中华实验和临床感染病杂志，2020,14(6):页码待定。
19.贺彩妮，李彧，葛蘅，魏伏，马晓桃，王文俊，高宁，段朝阳，纪泛扑*.基于索磷布韦方案治疗HCV相关性肾小球肾炎的效果和安全性.临床肝胆病杂志, 2019, 35(8): 1714-1718.
联系方式电话：15319435860
邮箱：jifanpu1979@163.com;infection@xjtu.edu.cn
